May 19, 2026

Top 10 High-Impact Clinical Guidance Updates for Board-Certified Physicians

A structured framework of guidelines, consensus statements, therapies, and clinical tools used across practice.

Conexiant

May 18, 2026

Top 10 States with the Lowest Costs for Running a Medical Practice

These 10 states posted some of the lowest 2026 Medicare practice expense GPCI among states that CMS treats as a single statewide locality, with broader price levels and selected malpractice or tax indicators adding context.

Conexiant

May 14, 2026

Physicians Exiting Practice Earlier

Researchers identify burnout-associated workplace pressures and caregiving responsibilities as major contributors to physician attrition.

Conexiant

May 14, 2026

TEASE Program Builds Case for Gildeuretinol in Stargardt

Philip J. Ferrone, MD, FASRS, reviewed data on gildeuretinol and discussed the ongoing NORTHSTAR pivotal trial at Retina World Congress.

Retinal Physician

May 14, 2026

FDA Updates: Retina Trials and Regulatory Pathways

William M. Boyd, MD, director of the FDA’s Division of Ophthalmology, discussed the agency’s evolving approaches to clinical evidence, trial design, and expedited regulatory pathways at the 2026 Retina World Congress meeting.

Retinal Physician

May 13, 2026

Diabetes Risk Scores: Beyond Glucose

Multi-ancestry polygenic models identify high-risk patients traditional screening may miss

Conexiant

May 13, 2026

Medical Oddities: Ancient Practice Calms Modern BP

Ancient workouts, anxious ears, tea gains, limb regrowth, and furry tongues collide.

Conexiant

May 13, 2026

Chronotherapy Trial Tests Sleep Timing in Adolescents

Two-week chronotherapy trial evaluates circadian phase, sleep duration, and alignment outcomes.

Conexiant

May 12, 2026

A New Solvation Strategy for Zinc Batteries

Spectroscopy and scattering reveal how ionic liquids reorganize water and zinc ion solvation in aqueous electrolytes

The Analytical Scientist

May 11, 2026

New Label Expansion in Generalized Myasthenia Gravis

Phase 3 ADAPT SERON data supported efgartigimod use across antibody subtypes often underrepresented in trials.

Conexiant